You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

HLA-B*5701 Screening

HLA-B*5701 screening significantly reduces the risk of an ABC hypersensitivity reaction (HSR)[1]

Go To Close TopScreening for the HLA-B*5701 Allele Should Be Performed Before Prescribing TRIUMEQ[1]

Prospective HLA-B*5701 screening: No immunologically confirmed HSR and significant reduction of clinically suspected HSR in the PREDICT-1 study[2]

10116320_Core Claims GLOBAL_48w_Bar_v10

Clinical description of HSRs:[2]

  • Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.
  • Other key symptoms include: gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise

If suspected:[2]

  • TRIUMEQ must be stopped without delay, even In the absence of the HLA-B*5701 allele
  • After stopping treatment with TRIUMEQ for a suspected HSR, TRIUMEQ or any other medicinal product containing ABC or Dolutegravir, must never be re-initiated


Guidelines recommended:[3],[4]

  • EACS and DHHS guidelines recommend screening for HLA-B*5701 before starting ABC-containing antiretroviral therapy, if not previously tested.


  1. Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to Abacavir. N Engl J Med. 2008;358:568-579.TRIUMEQ Summary of Product Characteristics.
  2. TRIUMEQ Summary of Product Characteristics.
  3. European AIDS Clinical Society. Guidelines. Version 8.1. October 2016. . Accessed Dec, 2016.
  4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. July 14, 2016. Accessed May 1, 2016.

For further information, please see the Summary of Product Characteristics.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Tivicay & Triumeq is registered trademark of the GlaxoSmithKline Group of Companies